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Background: Liver injury is a known feature of severe malaria, but is only incidentally investigated in uncompli-
cated disease. In such cases, drug-induced hepatotoxicity is often thought to be the primary cause of the observed
liver injury, and this can be amajor concern in antimalaria drug development.We investigated liver function test
(LFT) abnormalities in patients with imported uncomplicated malaria, and in Controlled Human Malaria Infec-
tion (CHMI) studies.
Methods: Clinical and laboratory data from484 importedmalaria cases and 254 CHMI participants were obtained
from the Rotterdam Malaria Cohort database, and the Radboud University Medical Center database (between
2001 and 2017), respectively. Routine clinical LFTs, clinical proﬁles, parasite densities, hematological, and inﬂam-
mation parameters were assessed in 217 patients with imported falciparum malaria upon admission, and from
longitudinal data of 187 CHMI participants.
Findings:Upon admission, theproportion of patientswith importeduncomplicatedmalaria and elevated liver en-
zymes was 128/186 (69%). In CHMI, 97/187 (52%) participants showed LFT abnormalities, including mild (64%,
N1.0 ≤ 2.5× upper limit of normal (ULN)), moderate (20%, N2.5 ≤ 5.0xULN) or severe (16%, N5.0xULN). LFT abnor-
malities were primarily ALT/AST elevations and to a lesser extent γGT and ALP. LFT abnormalities peaked shortly
after initiation of treatment, regardless of drug regimen, and returned to normal within three to six weeks. Pos-
itive associations were found with parasite burden and inﬂammatory parameters, including cumulative inﬂam-
matory cytokine responses and oxidative stress markers (r = 0·65, p = 0·008, and r = −0·63, p = 0·001,
respectively).
Interpretation: This study shows that reversible liver injury is a common feature of uncomplicated falciparumma-
laria, most likely caused by an enduring pro-inﬂammatory response post treatment. The recognition of this phe-
nomenon is of clinical relevance for individual patient care as well as clinical development of (new) antimalarial
drugs.
Fund: PATH Malaria Vaccine Initiative (MVI)
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Malaria continues to play a critical role in the global infectious dis-
ease burden with signiﬁcant morbidity and mortality, especially in
sub-Saharan Africa. International travelers are also at risk in N90
countries worldwide, mainly in Africa, Asia, and the Americas [1]. Clini-
cal malaria is characterized by a systemic inﬂammatory response in-
duced by asexual Plasmodium parasites. Plasmodium falciparum is
responsible for most malaria-related deaths globally [1]. Severity of dis-
ease is determined by multiple factors, including parasite species and
timing of antimalarial treatment [2]. The majority of severe falciparum
malaria manifestations are most likely related to cytoadherence
of parasitized red blood cells (RBCs) to the vascular endothelium, to
each other (platelet-mediated agglutination) [3], or to uninfected
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erythrocytes (rosetting) [4,5]. The subsequent sequestration in the mi-
crovasculature results in decreased local oxygen supply and a disturbed
metabolism, eventually leading to vital organ failure.
Hepatic dysfunction and jaundice are common features of severe
malaria [6–9]. Histopathological changes in the liver range fromhepato-
cyte necrosis, granulomatous lesions, Kupffer cell hyperplasia, malarial
pigmentation, cholestasis, monocyte inﬁltrations to malarial nodules
[7,10,11]. These complications can contribute signiﬁcantly to liver fail-
ure and other systemic complications [9,12,13]. The underlying patho-
genesis of liver damage is largely unknown. Furthermore, liver
involvement has only been incidentally investigated in uncomplicated
malaria [14–16].
Previously, we regularly observed pronounced elevations in liver
function tests (LFTs) often shortly upon initiation of curative treatment
in patients with imported uncomplicated malaria. We hypothesized
that liver injury might arise through a mechanism other than drug-
induced hepatotoxicity, or the substantial sequestration observed in se-
vere disease [4,17]. Understanding this clinical feature of uncomplicated
malaria could support clinicians in drug-related decisionmaking, and in
particular drug development, where frequency of adverse hepatic reac-
tions is a leading concern. Here, we performed a retrospective analysis
to determine the frequency of LFT abnormalities in patients with
imported uncomplicated malaria, and used longitudinal prospective
data of controlled humanmalaria infection (CHMI) studies to further in-
vestigate the signiﬁcance, dynamics and pathophysiological basis of
liver injury.
2. Methods
2.1. Study design and population
Clinical and laboratory data from 484 imported malaria cases and
254 individuals participating in 17 CHMI studies were obtained from
the Rotterdam Malaria Cohort database, and the Radboud University
Medical Center database, respectively. The Rotterdam Malaria Cohort
consists of patients diagnosed with imported malaria who presented
at the Rotterdam Harbour Hospital or the Erasmus University Medical
Center between 2002 and 2017. For this study, clinical and laboratory
data from patients with imported P. falciparum malaria were selected
(S1 ﬁgure). Patients with a known history of liver disease, or concomi-
tant infections at admission were excluded (e.g. hepatitis B, HIV, schis-
tosomiasis, urinary tract infections, and respiratory tract infections).
Furthermore, patients that received antimalarial treatment prior
admission were also excluded. Data on concomitant medication use
other than antimalarial treatment, antipyretic therapy (e.g. acetamino-
phen) or information on (chronic) alcohol intake were not available.
Because of the retrospective nature of the analysis and use of
anonymized data, ethical approval or informed consent was not neces-
sary, as stated in the Medical Research involving Human Subject Act
(WMO).
Healthy malaria-naïve male and female participants aged
18–35 years were recruited for the CHMI studies between 2001 and
2016. Extended screening included hematology and biochemistry pa-
rameters, serology for asexual stages of P. falciparum, and hepatitis B, C
andHIV, as previously described [16,18]. All study participants provided
written informed consent at screening visit. All clinical trials were ap-
proved by the Radboudumc Committee on Research Involving Human
Subjects (CMO), the Central Committee on Research Involving Human
Subjects (CCMO) of the Netherlands, or the Western Institutional
Review Board (WIRB). The studies were conducted according to the
principles outlined in theDeclaration ofHelsinki andGood Clinical Prac-
tice standards, and registered at ClinicalTrials.gov. Study EHMI-3, con-
ducted in 2001, was not registered in an online database such as
ClinicalTrials.gov.
2.2. Controlled human malaria infection
CHMI participants were all challenged by bites of malaria-infected
mosquitoes or direct venous inoculation of sporozoites/blood stage par-
asites. The challenges were conducted with different parasite clones:
NF54 (airport malaria) [19], 3D7 (clone of NF54) [20], NF135
(Cambodia) [21], and NF166 (Guinea, West Africa) [22]. Daily blood
sampling included parasitological assessment (thick blood smears and
qPCR) and/or safety laboratory parameters.
Research in context
Evidence before this study
We conducted an online literature search on liver function test
(LFT) abnormalities in uncomplicatedmalaria using PubMed for ar-
ticles published up to May 1st, 2018. Articles were searched by
title and abstract using the terms “hepatic dysfunction” or “liver in-
jury” or “liver function test” or “liver enzymes” or “transaminases”,
with either “malaria” or “uncomplicatedmalaria” or “non-severema-
laria” without language restrictions. Some articles cited in the
screened publications were also included. We screened 58 arti-
cles, 26 of which described liver injury in malaria focusing on se-
vere disease. Only four contained information on LFT
abnormalities in uncomplicated disease specifically. Most other
studies described hepatic adverse reactions in the context of anti-
malarial drugs. Themost descriptive studywas a recent retrospec-
tive study by Woodford et al… that provides data on LFT
dynamics. Ramirez et al described the proportion of LFT abnormal-
ities on admission day in a case control study. In these studies, no
clear associations were found between clinical and demographic
factors, and LFT abnormalities in uncomplicated malaria. The
pathophysiological basis of liver injury has only been described in
animals to date.
Added value of this study
To our knowledge, this is the first study using longitudinal and pro-
spective data fromCHMI studies to characterize liver injury specif-
ically in uncomplicated falciparum malaria. This study adds novel
insights into clinical relevance, dynamics and pathophysiological
basis of liver injury.We provide evidence that the underlying path-
ogenesis of liver injury in uncomplicated malaria is unlikely to be
related to hepatotoxicity of antimalarials, and conceivably differs
from that during severe malaria. Induced inflammation per se
may be a major driver of liver injury since parasite load in CHMI
is extremely low but sufficient to effect systemic inflammation
and oxidative stress.
Implications of all the available evidence
Recognizing and understanding this relatively common phenome-
non is of significant importance for both drug-related clinical deci-
sion making and development of antimalarial drugs. Incorrect
attribution of liver injury to an antimalarial drug can lead to unnec-
essary discontinuation or shifts in drug regimens; instead, a more
expectative approach might be warranted. Clinical trials testing
the safety and efficacy of novel antimalarials should carefully
(re)consider unnecessary early abrogation of promising drugs
with supposed hepatotoxic effects. Supportive therapeutics with
hepatotoxic potential during a malaria infection should, however,
be limited or given with appropriate monitoring.
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2.3. Laboratory investigations
All clinical laboratory data were assessed by standard hematological
and biochemical tests on peripheral blood specimens. Biochemical liver
tests included: aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), gamma-glutamyl transferase (γGT), alkaline phosphatase
(ALP), lactate dehydrogenase (LD), and total bilirubin. Reference labora-
tory values for AST were b 30 or b 35 U/L (female or male); ALT b35 or
b 45 U/L (female or male); γGT b40 or b 55 U/L (female or male); ALP
b100 or b 115 U/L (female or male); total bilirubin b17 μmol/L; LD
b250 U/L (S2 table).
2.4. Inﬂammatory cytokines and oxidative stress analysis
Inﬂammatory cytokines (IL-1β, IFN-α, IFN-γ, TNF-α, MCP-1, IL-6,
IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33) were determined
in study CHMI-trans1 using ﬂow-based multiplex (Legendplex). For
the oxidative stress analysis, TaqMan gene expression Assays (Applied
Biosystem) were used to measure antioxidant gene expression levels
for Superoxide dismutases (SOD1 and SOD2), Nitric oxide synthase
(NOS3), Catalase (CAT), Peroxiredoxin (PRDX1) and Glutathione
S-transferase Kappa (GSTK1) from whole blood by using qPCR (S1 Ma-
terial). The cumulative anti-oxidant and cytokine responseswere deter-
mined through transformation of data into a Z-score (each value
subtracted by the mean of the group and divided by the SD of the
group).
2.5. Deﬁnitions
Liver function test (LFT) abnormalitieswere graded using an adapta-
tion of the World Health Organization (WHO) Adverse Event Grading
System 2003:mild LFT elevations (N1·0 ≤ 2·5× upper limit of normal
(ULN)), moderate (N2·5 ≤ 5·0xULN), and severe (N5·0XULN) eleva-
tions. Imported malaria patients were classiﬁed as having uncompli-
cated malaria by absence of WHO criteria 2014 [23] for severe
P. falciparummalaria on admission or during hospitalization. Abnormal
bilirubin levels were not included in the incidence or grading of LFT ab-
normalities, since the bilirubin increases found in the imported malaria
casesmost likely reﬂect haemolysis and could possibly bias the elevated
liver enzyme prevalence in imported malaria. Similarly, lactate dehy-
drogenase (LD) was not included in the incidence or grading of LFT ab-
normalities, due to its strong relation to haemolysis and low liver
speciﬁcity. Patients with imported malaria were considered partially-,
semi-, or non-immune. In short, patients born in a malaria-endemic
country living in the Netherlands were considered partially immune.
Patients that were born and still residing in a malaria-endemic area
were presumed semi-immune. All other patients were considered
non-immune [24]. Data on previous episodes of malaria were not
available.
The parasite load was estimated by measuring the area under the
curve of parasitaemia over time, and computed by GraphPad Prism 5
(2009, San Diego California USA).
2.6. Statistical analysis
All data were analyzed with GraphPad Prism 5 or SPSS software ver-
sion 24 (IBM Inc., Chicago, IL, USA). Descriptive analyses are presented
as percentages, mean with standard deviation, or median with inter-
quartile range. Mann Whitney U test was used for comparison of non-
normal continuous data or independent groups/samples. Chi square
test or Fisher's exact test was used for comparison of qualitative vari-
ables and for determining association between various variables. Corre-
lation between different parameters was assessed by Spearman's rho.
A P-value of b0·05 was considered as statistically signiﬁcant.
3. Results
The general characteristics on admission of the 217 included pa-
tients with imported P. falciparum malaria are shown in Table 1 and
S1 table. On admission day, LFTs were increased in 128/186 (69%) of
patients with uncomplicated falciparum malaria (Table 1) and 27/31
(87%) in severe disease (S1 table). In uncomplicated disease, abnormal-
ities appeared to be mild in 93/186 (50%), moderate in 26/186 (14%),
and severe in 9/186 (4·8%) of the cases. The median ALT of all
uncomplicated malaria patients with LFT abnormalities was 48
U/L (range 15–242 U/L, IQR 34–68 U/L), and the median AST was
41 U/L (range 9–326 U/L, IQR 31–63 U/L). The median γGT was 71 U/L
(range 20–447 U/L, IQR 49–113 U/L), the median ALP was 83 U/L
(range 36–265 U/L, IQR 64–101 U/L), the median total bilirubin was
22 μmol/L(3–115 μmol/L, IQR 17–43 μmol/L), and the LD was 286
μmol/L (range 52–656 μmol/L, IQR 113–346 μmol/L). No statistically sig-
niﬁcant differenceswere found between ages, gender, or immune status
in patients with- or without LFT abnormalities. Furthermore, LFT abnor-
malities appeared in all treatment groups (Table 1). In a sub-group anal-
ysis of the malaria cohort, increases in LFT abnormalities were also
found in 23/50 (46%) of the patients with a Plasmodium vivax infection
(S1 table). No signiﬁcant differences in other parameters than in LFTs
between cases with and without LFT abnormalities were observed
(S1 table).
Table 1
General characteristics of patients with imported uncomplicated falciparum malaria on
admission day.
No LFT# LFT# p-value
(n = 58) (n = 128)
Age 37 (29–50) 39 (30–47) 0·960
Gender 0·390
Female 18 (31%) 32 (25%)
Male 40 (69%) 96 (75%)
Immunity 0·270
Unknown 3 (5%) 1 (1%)
Non-immune 27 (47%) 57 (45%)
Partially 26 (45%) 65 (51%)
Semi 2 (3%) 5 (4%)
Parasitaemia/μL 7·611
(1·582–44·550)
5·466
(1·146–47·100
0·811
AST (U/L) 21 (17–26) 41 (31–63) b0·001
ALT (U/L) 25 (19–30) 48 (34–68) b0·001
γGT (U/L) 30 (20–37) 71 (49–113) b0·001
Alkaline phosphatase
(U/L)
65 (57–79) 83 (64–101) b0·001
Bilirubin (total) (μmol/L) 21 (10–28) 22 (15–31) 0·039
LD (U/L) 275 (196–304) 286 (113–346) 0·181
Haemoglobin (mmol/L) 8·1 (7·4–8·9) 8·7 (7·7–9·4) 0·006
Leukocytes (x109/L) 4·9 (4·0–5·8) 4·9 (3·6–6·4) 0·863
Lymphocytes (x109/L) 0·9 (0·6–1·4) 0·9 (0·6–1·4) 0·998
Thrombocytes (x109/L) 125 (69–174) 87 (56–131) 0·008
CRP (mg/L) 64 (30–116) 106 (56–158) 0·001
Creatinine (μmol/L) 95 (81–108) 95 (81–108) 0·400
Urea (mmol/L) 4·9 (3·9–6·2) 5·2 (4·0–6·4) 0·498
Sodium (mmol/L) 136 (133–138) 135 (133–138) 0·578
Potassium (mmol/L) 3·8 (3·5–4·2) 3·7 (3·5–4·0) 0·299
Lactate (mmol/L) 1·3 (1·0–1·5) 1·4 (1·1–1·9) 0·017
Temperature (°C) 37·6 (36·9–38·8) 38·9 (37·5–39·5) 0·001
Treatment 0·532
atovaquone/proguanil 50 (86%) 108 (84%)
quinine 4 (7%) 4 (3%)
artemether/lumefantrine 4 (7%) 2 (2%)
artesunate 13 (10%)
chloroquine 1 (1%)
Severity LFT# n/a
Mild LFT# n/a 93 (73%)
Moderate LFT# n/a 26 (20%)
Severe LFT# n/a 9 (7%)
All data are presented as median (IQR) or N (%). LFT#= liver function test abnormalities.
Statistical differences are tested using Mann-Whitney or Chi square. Clinical laboratory
reference ranges can be found in S2 table.
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Table 2
Overview of CHMI studies.
Study Year Challenge Treatment drug Subjects with
parasitaemia
(n)
Mean peak
parasiteamia (Pf/
μL)
Subjects
with
LFT#a (n
(%))
Severity Treatment
criterion
LFT
timepoints
Registered
mild moderate severe
EHMI-3 2001 3D7- mosquito bite chloroquine 5 21.6 4 (80) 2 2 0 48 h after positive
TSb
multiple
timepointse
–
EHMI-8A 2007 NF54- mosquito bite artemether-lumefantrine 5 15.1 LFTs not measured during infectiond positive TSb – NCT00442377
LSA-3 2008 NF54- mosquito bite artemether-lumefantrine 18 26.7 18 (100) 10 4 4 positive TSb multiple
timepointse
NCT00509158
EHMI-8B 2009 NF54- mosquito bite atovaquone-proguanil 7 3.7 4 (57) 4 0 0 positive TSb Standardc NCT00757887
TIP1 2010 NF54-NF135 mosquito bite atovaquone-proguanil 10 17.6 LFTs not measured during infectiond positive TSb – NCT01002833
TIP2 2010/2011 NF54- PfSPZ I.M.⁎ atovaquone-proguanil 15 43.6 5 (33) 4 0 1 positive TSb Standardc NCT01086917
ZonMw1 2011 NF54- mosquito bite atovaquone-proguanil 12 28.5 LFTs not measured during infectiond positive TSb – NCT01218893
EHMI-9 2011 3D7- mosquito bite or BS
challenge⁎⁎
atovaquone-proguanil 19 9.5 11 (58) 9 1 1 positive TSb standardc NCT01236612
ZonMw2 2012 NF54- mosquito bite atovaquone-proguanil 9 27.8 6 (67) 6 0 0 positive TSb standardc NCT01422954
TIP4 2012 NF135- mosquito bite atovaquone-proguanil 19 81.1 8 (42) 6 2 0 positive TSb standardc NCT01660854
TIP3 2012 NF54-NF135-NF166 mosquito
bite
atovaquone-proguanil 15 37.4 LFTs not measured during infectiond positive TSb – NCT01627951
TIP5 2012/2013 NF54- mosquito bite atovaquone-proguanil 21 15.5 11 (52) 4 6 1 positive TSb standardc NCT01728701
BMGF2a 2014 NF54-NF135-NF166 mosquito
bite
atovaquone-proguanil 20 20.1 LFTs not measured during infectiond 2 pos. qPCR
(≥500Pf/mL)
– NCT02149550
BMGF1 2014 NF54- mosquito bite atovaquone-proguanil 8 0.1 0 (0) 0 0 0 pos. qPCR
(N100Pf/mL)
standardc NCT02080026
BMGF2b 2015 NF54-NF135-NF166 mosquito
bite
atovaquone-proguanil 31 1.5 7 (23) 6 0 1 pos. qPCR
(N100Pf/mL)
standardc NCT02098590
BCG-EHMI 2016 NF54- mosquito bite atovaquone-proguanil 19 1.0 7 (37) 6 1 0 pos. qPCR
(N100Pf/mL)
standardc NCT02692963
CHMI-trans1 2016 3D7- mosquito bite sulfadoxine-pyrimethamine/
piperaquine
16 20.0 16 (100) 5 3 8 positive TSb multiple
timepointse
NCT02836002
Total subjects with LFTs measured 187 97 (52) 62
(33)
19 (10) 16 (9)
Total subjects with LFTs measured (thick smear studies) 129 83 (64) 50
(39)
18 (14) 15
(12)
Total subjects with LFTs measured (qPCR studies) 58 14 (24) 12
(21)
1 (2) 1 (2)
a liver function test abnormalities.
b TS = thick smear.
c standard LFT measurements at 3 time-points: baseline, 2 days after treatment, and at the end of study.
d LFTs are only measured on baseline and at the end of study.
e N3 LFT measurement time-points (range of 4–13).
⁎ intra-muscular injection.
⁎⁎ blood stage challenge.
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To better deﬁne the dynamics and basis of liver injury, we used data
of CHMI studies, which entails extensive screening to minimise con-
founding effects. Longitudinal data of 17 CHMI studies with a total of
254 participants with patent parasitaemia, showed that LFTs were ele-
vated in 97/187 (52%) of the participants with LFTsmeasured during in-
fection (Table 2). In most cases standard LFT measurement time-points
were obtained at baseline, 2 days post-treatment, and at the end of
study. Elevations were primarily limited to ALT/AST elevations, and to
a lesser extent, to γGT and ALP. Increased transaminases were found
in 83/129 (64%) of the CHMI participants when treated at positive
thick smear (treatment threshold of ~ N 5 parasites/μL), including mild
(50/83 (60%), N1·0 ≤ 2.5xULN), moderate (18/83 (22%), N2·5
≤ 5·0xULN) and severe (15/83 (18%), N5·0xULN) elevations (Table 2).
The incidence of LFT elevations was 14/58 (24%) in volunteers treated
at positive qPCR (treatment threshold of N0·1 parasites/μL), including
mild (12/14 (86%)), moderate (1/14 (7%)), and severe (1/14 (7%)) ele-
vations (Table 2;). Among all CHMI participants the median peak ALT
was 69 U/L (range 13–870 U/L, IQR 46–98 U/L), and median peak
AST was 52 U/L (range 22–723 U/L, IQR 43–85 U/L) from all sample col-
lection time-points during infection. Median peak γGT was 40 U/L
(range 11–184 U/L, IQR 26–68 U/L), median peak ALP was 79 U/L
(range 17–218 U/L, IQR 67–94 U/L), median peak total bilirubin was
11 μmol/L (range 3–31 μmol/L, IQR 9–15 μmol/L), and median peak LD
was 422 μmol/L (range 170–981 μmol/L, IQR 198–396 μmol/L). Only
9/187 (5%) showed mild elevations (N1·0 ≤ 2·5xULN) of total bilirubin
levels.
When more frequently assessed over the course of the study
(2 CHMI studies, n = 34), mild LFT elevations became apparent just
prior to initiation of treatment (Fig. 1). The majority of LFT abnormali-
ties exceeded the upper limit of normal on the day of treatment, and
peaked around 2–6 days after initiation of antimalarials. This corrobo-
rates with data from EHMI-3 (n = 5) where treatment is initiated
48 h after a positive thick smear. The observed abnormalities were tran-
sient, normalizing at study end (aroundday 35–42 after challenge infec-
tion). Furthermore, a distinct pattern of timing of peak of transaminase
elevations is found between individuals. Some participants show peak
elevations early after treatment and othersmore delayed. These speciﬁc
patterns, as well as the severity of the observed abnormalities, seem re-
gardless of different drug regimens used.
To compare the dynamics of LFT abnormalities between CHMI and
imported cases, data of 51 patients with imported uncomplicated ma-
laria with multiple LFTs measurements were also obtained to analyze
the course of LFT elevations (S2 ﬁgure). A similar LFT pattern was
found in both naturally-acquired infections and CHMI participants,
where LFT elevations peaked after treatment and normalized during
follow-up. In contrast to CHMI-participants, total bilirubin levels in pa-
tients with imported P. falciparummalaria were increased on admission
day, suggesting a concomitant haemolysis most likely due to 2–3 log
higher parasite densities.
3.1. Association between parasite load & liver function tests
CHMI participants with LFT abnormalities presented with a higher
parasite load than those without LFT abnormalities (p b 0.001), al-
though the range was relatively large (Fig. 2A). There was a positive
association between LFT values and parasite load in the CHMI studies
(r=0·33, p b 0.001) (Fig. 2B). No signiﬁcant differenceswere foundbe-
tween the different groups of LFT severity grades. In addition, in clinical
cases with imported uncomplicated P. falciparum infections, a positive
association was found between parasite density on admission day, and
LFT abnormalities (r = 0·25, p = 0.005).
4. Clinical laboratory parameters and liver function tests
Analysis of clinical laboratory parameters in CHMI participants
showed that lowest platelet, leukocyte, and lymphocyte counts, as
well as maximum LD levels, independently associated with LFT abnor-
malities (p b 0.0001, p = 0.01, p b 0.0001, p b 0.0001, respectively)
(Fig. 3). However, prior to treatment these parameters poorly predicted
LFT abnormalities.
We hypothesized that inﬂammation, well known to be involved in
malaria pathogenesis, might play a role in these abnormalities. In the
imported uncomplicated malaria cases, C-reactive protein (CRP) was
increased on the day of admission in patients with LFT abnormalities
Fig. 1. Course of liver function test (LFT) levels during CHMI. Multiple LFT measurements of the LSA-3 and CHMI-trans1 study (n= 34). LFT sampling time-points differ between studies
and individual participants. The line interruption indicates sampling time-points prior- and post-treatment. ALT = alanine aminotransferase, AST = aspartate aminotransferase, γGT=
gamma glutamyl transferase, ALP = alkaline phosphatase. Orange curves are the median of all grey individual participants curves per LFT.
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(p b 0.001) (Fig. 2C). A statistically signiﬁcant difference was found in
maximum d-dimer levels in CHMI participants with or without LFT ab-
normalities (p b 0.001) (Fig. 2D).
Amore extended pro-inﬂammatory cytokine panelwasmeasured in
one CHMI study (CHMI-trans1, n=16) one day after treatment, show-
ing a positive correlation between IFNγ, IL-6, and IL-8, and peak of the
LFT abnormalities, p = 0.039, p = 0.049, and p = 0.015, respectively
(S3 table). A strong positive associationwas also found between the cu-
mulative inﬂammatory responses (IFNγ, MCP-1, IL-6, IL-8, IL-10,
IL12p70, IL-17a, IL-18) and LFT abnormalities (r = 0.65, p = 0.008)
(Fig. 4). In a second study (EHMI-8B study, n = 7), a similar positive
trend was found for d-dimer, CRP, IFNγ, and IL-6 values (S3 ﬁgure).
Finally, a number of anti-oxidant markers were measured to further
deﬁne the nature of the induced inﬂammatory response in relation to
LFT abnormalities. A signiﬁcant reduction in the average of anti-
oxidant gene expression SOD1 (p = 0.03), SOD2 (p = 0.001), NOS3
(p b 0.0001), CAT (p b 0.0001), and GTSK1 (p b 0.0001) and an increase
in expression of PRDX1 (p = 0.007) was observed during the malaria
infection (one day after treatment) (S4 ﬁgure). The cumulative anti-
oxidant response of these markers through transformation into a
Z-score, showed a negative association between the anti-oxidant re-
sponse and the LFT abnormalities (r =−0.63, p = 0.001) (Fig. 4). All
markers normalized by the end of the study.
5. Discussion
This study shows that abnormalities in liver function test (LFT) are a
relatively frequent ﬁnding in uncomplicated falciparum malaria, and
occur regardless of the choice of drug regimen. These abnormalities
are transient in nature, resolving within 3–6 weeks. The typical pattern
of LFT elevations is primarily limited to ALT/AST elevations, and to a
lesser extent, to γGT and ALP, and peaks in particular two to six days
after initiation of treatment. Furthermore, the study shows a signiﬁcant
association between LFT elevations and parasite load, inﬂammatory
markers and reduced expression of oxidative stress markers. Early
treatment based on qPCR thresholds can decrease the occurrence and
severity of LFT abnormalities in CHMI.
Hepatic dysfunction is a well-known feature of severe malaria, con-
tributing to clinically signiﬁcant complications such as hypoglycaemia,
metabolic acidosis, impaired drug metabolism, and ﬁnally organ failure
[8,12].Malaria-associated liver damage in uncomplicatedmalaria, how-
ever, has rarely been investigated so far [25]. Observational studies are
often restricted in number and limited to admission samples only [15],
therefore, underestimating incidence and severity. Other studies do
not differentiate non-severe from severe disease in their analysis
[9,14,26]. This study speciﬁcally advocates the relevance in relation to
potential clinical implications in uncomplicated disease, which consti-
tutes the vast majority of clinical malaria cases. This study highlights
that LFT abnormalities can be severe (up to N20 xULN), but are appar-
ently fully reversible upon parasitological cure, corroborating previous
reports [25–27].
The observed liver injury seems to have a hepatocellular basis, as in-
dicated by the disproportionate elevation in serum transaminases rela-
tive to alkaline phosphatase. Peak bilirubin levels precede antimalarial
treatment in imported malaria cases but not CHMI. This suggests that
these elevations are likely due to haemolysis leading from higher
parasitaemia in these patients compared to CHMI volunteers. Similarly,
Woodford et al. show that bilirubin elevations in clinical cases peak on
admission day, resolving early after treatment in contrast to the later oc-
curring peak of transaminases [14]. The absence of clearly elevated bil-
irubin levels in CHMI adduces that these events may not result in a
functional liver impairment, since conjugation of bilirubin occurred nor-
mally. Serum albumin or clotting factors were not tested in the current
study, and therefore, it cannot be formally excluded that biosynthetic
capacity of the liver may be compromised. The absolute increase in
serum transaminases is of little prognostic value since the liver can
Fig. 2. Parasite load, inﬂammation markers, and liver function test (LFT) abnormalities. A) Parasite load in CHMI without- (no LFT#), and with LFT abnormalities (LFT#). Error bars
represent median with inter-quartile range. Parasite load as the area under the curve (AUC) represents the total parasite exposure over time. B) Association of parasite load and
severity of liver function abnormalities in x the upper limit of normal of LFTs (xULN of LFTs) in CHMI subjects. C) C-reactive protein (CRP) levels of patients with imported
uncomplicated P. falciparummalaria on admission day. D) Maximum d-dimer levels measured in participants with LFT abnormalities (LFT#) in CHMI. D-dimer data are from 6 CHMI
studies (n= 81) with multiple samples measured during challenge infection. Error bars represent the median with inter-quartile range. ***p b 0.001.
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recover frommost forms of acute injury, due to its large regenerative ca-
pacity. In absence of symptoms such as haemorrhage or altered con-
sciousness, signiﬁcant hepatic dysfunction seems highly unlikely in
patients without history of liver disease.
The potential contribution of infection transformation, from the liver
stage to blood stage infection, to LFT abnormalities remains uncertain.
However, similar LFT abnormalities are found CHMI studies with a
blood stage challenge, where the liver stage of the parasite is
circumvented [14]. This, together with the observation that no substan-
tial LFT abnormalities are found on day 6–7 (day of liver schizont rup-
ture), makes it less likely that the liver stage can cause signiﬁcant LFT
abnormalities on its own. It is unknown if the liver stage could inﬂuence
the severity of the observed abnormalities.
This study provides evidence that the underlying pathogenesis of
liver injury in uncomplicated malaria conceivably differs from severe
malaria. In severe falciparum malaria, tissue damage is thought to be
at least partly related to decreased oxygen supply and disturbedmetab-
olisms due to parasite sequestration in the microvascular capillary sys-
tem [7,17]. However, in CHMI only very low parasite densities are
present and sequestration likely limited. Systemic inﬂammation with
leukocytopaenia, thrombocytopaenia, increased d-dimer, CRP, and
IFN-y concentrations is a typical hallmark of malaria even at the very
low density of parasitaemias as observed after CHMI [28,29]. This
study shows a clear relationship between these parameters and LFT
abnormalities in falciparummalaria. Togetherwith the timing of LFT ab-
normalities post treatment, and the presence of low-density
parasitaemia, this suggests an inﬂammation-based mechanism of liver
injury. Similarly, lung injury with impaired alveolar-capillary function
is described to deteriorate after antimalarial treatment, reﬂecting a
prolonged inﬂammatory response to parasite killing [30]. Histopathol-
ogy of lung tissue in vivax malaria supports this hypothesis with an in-
crease in alveolar-capillary monocytes and pulmonary phagocytic cell
activity after initiation of treatment [31]. An adjacent hypothesis de-
scribes platelet sequestration as a downstream promoter of liver injury
by exacerbating local inﬂammation and leukocyte accumulation [32],
which correlates with the observed thrombocytopaenia and
leukocytopaenia. Interestingly, although inﬂammation-induced liver in-
jury is common in other infectious diseases (e.g. extrahepatic bacterial
infection and sepsis), it seems to predominantly have a cholestatic na-
ture in contrast to uncomplicated malaria [33].
Fig. 3. Clinical laboratory parameters and liver function test (LFT) abnormalities in CHMI. Maximum lactate dehydrogenase (LD), and minimum platelets, leukocytes, and lymphocytes
measured in CHMI participants without-, and with LFT abnormalities (LFT#). Error bars represent the mean with SD. **P = 0·004; ***p b 0·001.
Fig. 4.Association between liver function test abnormalities, and cumulative cytokine levels and cumulative anti-oxidant gene expression. The cumulative cytokine score comprises IFNγ,
MCP-1, IL-6, IL-8, IL-10, IL12p70, IL-17a, IL-18 and the cumulative anti-oxidant gene expression comprises SOD1, SOD2, NOS3, CAT, GTSK1, and PRDX1measured on 1 day after treatment
(DT + 1) in CHMI-trans1. Values are standardized as a Z-score. xULN of LFTs = x upper limit of normal range of liver function tests (LFTs). The xULN of LFTs values are the peak LFT
abnormalities measured from day 2 after treatment and the samples available onwards.
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Systemic inﬂammation is the net result of an interplay between
pro- and anti-inﬂammatory responses, and a shift towards a
pro-inﬂammatory status can cause malfunctioning of the host's mi-
tochondria in malaria, leading to organ damage [34]. The resulting
oxidative stress as observed in uncomplicated malaria is known to
play a role in pathogenesis [35]. For instance, lipid peroxidation
and antioxidant enzyme activity associate with cholestatic jaundice
in P. vivax patients [36], and oxidative stress causes hepatocyte apo-
ptosis in murine malaria models [37,38]. In this study, we show that
anti-oxidant gene expression is down-regulated for SOD1, SOD2,
NOS3, CAT, and GSTK1 during infection, and up-regulated for
PRDX1. This corroborates with data from rodent studies [39,40] and
a non-human primate study with P. knowlesi [41], where hepatic su-
peroxide scavenging systems, glutathione S-transferase, superoxide
dismutase and catalase, decrease during the course of a malaria in-
fection. This net result may be reduced clearance of radicals and sub-
sequent failure to protect cellular constituents from oxidative
damage.
Our ﬁndings reﬂect a need to understand and reassess LFT abnor-
malities in malaria. This will have signiﬁcant impact on clinical
decision-making and in drug development, where they are often
interpreted as drug-induced liver injury, particularly in malaria drug
studies [27,42]. For example, drug-related serious adverse events in a
recent multicentre trial comparing pyronaridine–artesunate or
dihydroartemisinin–piperaquine versus current ﬁrst-line therapies for
uncomplicated malaria were associated mainly with increased liver en-
zymes [43]. Incorrect attribution of liver injury to an antimalarial drug
can lead to unnecessary discontinuation or shifts in drug regimens, or
impede drug development. Given the diversity of drug regimens used,
it is unlikely that the observed LFT abnormalities in this study are caused
by antimalarials. Moreover, no marked deterioration of LFTs was ob-
served after a second, higher drug dose [16]. Our data does not support
distinct differences between drugs and severity or occurrence of LFT ab-
normalities. In linewithﬁndings fromWoodford et al., our data does not
show a clear relation between the severity of abnormalities found, the
pattern of early- or delayed transaminase elevations, and the different
drug regimens used in CHMI. Furthermore, the timing, varied and
often limited use of supportive medication (such as paracetamol,
known for dose-dependent hepatotoxicity) in CHMI does not support
a clear relationship with LFT abnormalities. It seems similarly improba-
ble that the observed injury is parasite strain-speciﬁc. Geographically
distinct P. falciparum strains were used in CHMI, and the imported
falciparum malaria cases were presumably caused by a wide diversity
of strains. In addition, non-falciparum malaria (e.g. Plasmodium vivax)
was also shown to increase LFT abnormalities.
The limitations of this study are related to the retrospective observa-
tional nature of some of the data. However, the longitudinal CHMI data
from healthy participants excludes the majority of confounding factors,
and provides a much more thorough description of LFT dynamics. Al-
though, we observed differences between CHMI and naturally-
acquired malaria cases, patients with sequential sampling data from
the latter seem to have similar LFT dynamics, and afﬁrmprevious obser-
vations [14].
This study shows that liver function test abnormalities are an under-
recognized but common feature of uncomplicated falciparum malaria.
The pathophysiological basis is most likely a pro-inﬂammatory re-
sponse associatedwith oxidative stress resulting in transient liver tissue
injury. Given the rapid and spontaneous resolution, and the absence of
clear functional liver impairment in uncomplicated malaria, these
events are unlikely to result in permanent subclinical liver damage.
Treatment should remain focused on fast parasite clearance, and a
more expectative approach might be warranted to avert unnecessary
discontinuation or shifts in antimalarials due to supposed drug-
induced liver injury. Nevertheless, supportive drugs with hepatotoxic
potential should be limited or given only with appropriate monitoring,
and adjunctive therapy that mediates systemic inﬂammation and
oxidative stress may have a potential role in helping to constrain ma-
laria progress into severe disease. Clinical trials testing the safety and ef-
ﬁcacy of novel antimalarials should consider the temporal relationship
between LFT abnormalities and infection. Importantly, unnecessary
early abrogation of further clinical development of promising drugs re-
lated to potential or supposed hepatotoxic effects should be carefully
(re)considered.
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